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CHIRAL SEPARATION OF THE ENANTIOMERS OF EPHEDRINE, 
AMPHETAMINE, METHAMPHETAMINE, MDA, MDMA, AND 
PHENTERMINE IN BLOOD USING LC-MS/MS 
 
 
ASHLEY MARIE VALLIER 
 
ABSTRACT 
Amphetamine-type stimulants are widely abused due to their ability to stimulate 
the central nervous system and elicit feelings of confidence, wakefulness, mood elevation, 
and euphoria.  After cannabis, amphetamines were the most abused group of illicit 
substances in 2016 according to the National Forensic Laboratory Information System 
Annual Report [1].  Included in this group is ephedrine, amphetamine, methamphetamine, 
3,4-methylenedioxyamphetamine (MDA), and 3,4-metheylenedioxymethamphetamine 
(MDMA).  Structurally, each of these compounds contain a chiral center, causing them to 
have an R-(-) and S-(+)- enantiomer (also called levo- and dextro-, respectively). 
 Despite their similarity, the R- and S- enantiomers display differing 
pharmacological effects, with the S-enantiomer producing a stronger, longer-lasting effect 
than the R-enantiomer.  Because of this, R-methamphetamine, for example, has therapeutic 
uses and is the active ingredient in some over-the-counter nasal decongestant products (e.g. 
Vicks® vapor inhaler).  S-methamphetamine, on the other hand, is generally found in illicit 
sources.  As a result of these chiral centers, these compounds have differing legal statuses. 
The aim of this research was to develop and validate a method for the separation and 
analysis of eleven amphetamine-class compounds in blood for forensic casework.  This 
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was accomplished using a liquid-liquid extraction and analysis on a liquid 
chromatography-tandem mass spectrometer (LC-MS/MS) (Agilent Technologies, Santa 
Clara, CA, USA).  Chromatographic separation was achieved using a Phenomenex Lux® 
AMP chiral column (Phenomenex, Torrance, CA, USA), under gradient aqueous and 
organic mobile phase conditions, with a total run time of just over 17 minutes.  The target 
analytes included 1S,2R-ephedrine, 1R,2S-ephedrine, R-amphetamine, S-amphetamine, 
R-methamphetamine, S-methamphetamine, phentermine, R-MDMA, S-MDMA, R-MDA, 
and S-MDA with 1S,2R-ephedrine-d3 and MDMA-d5 as the internal standards (Cerilliant, 
Round Rock, TX, USA).  
The analytical method was validated according to the Scientific Working Group for 
Forensic Toxicology guidelines (now a subcommittee of the Organization of Scientific 
Area Committees for Forensic Science), including the assessment of its linearity, limits of 
detection and quantitation, bias, precision, interferences, matrix effects, carryover, and 
processed sample stability [2].  The limit of detection (LOD) was 2 µg/L for all compounds 
except MDMA and MDA, which had LODs of 10 µg/L.  The lower limit of quantitation 
(LLOQ) and upper limit of quantitation (ULOQ) was 10 µg/L and 1000 µg/L, respectively, 
for all compounds.  The precision was within 15% for all analytes, with the bias extending 
outside the ±20% range for at least one set of samples for all analytes except 1S,2R-
ephedrine and both MDA enantiomers.  Matrix effect studies showed average ion 
enhancement (140%-361%), extraction efficiencies (60%-123%), and process efficiencies 
(105%-432%) across all analytes.  No interferences were detected from isotope internal 
standards, postmortem blood, antemortem blood, or 85 commonly seen drugs in forensic 
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casework.  No carryover was observed following injections of analytes at the ULOQ (1000 
µg/L). 
To demonstrate applicability in authentic casework, the method was applied to 28 
cases that had previously been analyzed using a non-chiral method.  By selectively 
identifying R- and S- enantiomers, this method may be used in forensics laboratories where 
the question of the licit or illicit use of amphetamines is of importance.  
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1. INTRODUCTION 
1.1 Amphetamines 
Amphetamines are a class of sympathomimetic compounds that primarily have 
stimulatory properties.  Their structure is very similar to the β-phenethylamine structure, 
which makes up the core endogenous neurotransmitters in the body, such as dopamine and 
serotonin [3].  Due to this structural similarity, amphetamines are able to stimulate the 
sympathetic nervous system and elicit feelings of confidence, wakefulness, mood 
elevation, and euphoria.  However, they can also cause anxiety, paranoia, irritability, 
insomnia, and fatigue.  The ability to cause such side effects varies from compound to 
compound based on the individual structure, which in turn affects how they are regulated 
by the government.  
For example, ephedrine has been used as a stimulant, concentration aid, and 
appetite suppressant.  It is not controlled in the United States, but its distribution is 
regulated under the Combat Methamphetamine Epidemic Act of 2005 [4].  Amphetamine 
has been used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), 
narcolepsy, obesity, and treatment-resistant depression, and is currently a Schedule II 
controlled substance [5].  Methamphetamine is also a Schedule II controlled substance, and 
has been used legally as a nasal decongestant and for ADHD treatment, although it is 
predominately synthesized in clandestine laboratories for use in the illicit market [5].  
Phentermine is a structural isomer of methamphetamine; however, unlike 
methamphetamine and other drugs in the amphetamine class, it does not contain a chiral 
center. It is a Schedule IV controlled substance and has been used as an anorectic [5].  
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The methylenedioxy derivatives of the amphetamine class, 3,4-
methylenedioxyamphetamine (MDA) and 3,4-methylenedioxymethamphetamine 
(MDMA), are unique in that the addition of the methylenedioxy structure causes these 
compounds to act as hallucinogens in addition to the stimulant activity that they have as 
amphetamines.  MDA and MDMA also cause feelings of increased intimacy, increased 
communication, and can induce a dissociative state [6].  Some negative side effects of their 
use include tachycardia, pupillary dilation, and ataxia.  Certain cases have also associated 
the use of MDMA with such adverse effects as rhabdomyolysis and renal failure [7].  
Although there has been some research in recent years regarding the use of MDMA as a 
treatment for post-traumatic stress disorder, MDA and MDMA are currently regarded as 
having no medical use in the United States and, as a result, are classified as Schedule I 
controlled substances [8].  
 
1.2 Amphetamine Abuse  
Despite most of these compounds having legitimate uses, amphetamines are widely 
abused.  Methamphetamine, amphetamine, and MDMA were all listed in the top 25 drugs 
found in laboratories across the United States according to the National Forensic 
Laboratory System (NFLIS) 2016 Annual Report [1]. 
Methamphetamine was the most common drug in the amphetamine class to be seen 
in forensic casework, and the second most identified illicit drug in the country, following 
cannabis [1].  Nationally, trends of methamphetamine use have been on an upswing since 
2011.  In 2016, 26% of all cases reported in laboratories reporting to NFLIS contained 
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methamphetamine [1].  Originally, illicit methamphetamine was typically obtained using 
a reductive cleavage of the hydroxyl group on ephedrine or pseudoephedrine.  However, 
since the Combat Methamphetamine Epidemic Act in 2005, clandestine manufacture has 
predominantly utilized a reductive amination of phenyl-2 propanone (P2P) to produce the 
final product [7].  
Amphetamine, on the other hand, is typically not synthesized in a clandestine 
laboratory.  Most of the abused amphetamine is sourced from legitimate pharmaceuticals, 
but has been diverted from its intended use.  Meant for treatment of ADHD, amphetamine 
has been abused by students studying for exams, drivers on nonstop trips, and military 
personnel on extended operations [9].  Amphetamine use has been on the rise since 2006, 
according to the NFLIS report [1]. 
MDA and MDMA are considered designer drugs, often found in a nightclub setting.  
As they have no accepted medical use, all MDMA and MDA must be synthesized 
clandestinely.  The most documented route of synthesis for MDMA is via oxidation of 
safrole oil, followed by condensing with an amine and reduction to the final product [10].  
MDMA use has cycled throughout the years, from a decrease in 2001-2003, increase 
through 2007, and sharp drop in 2010-2013 [1].  Current trends show a gradual increase of 
MDMA use since 2014 [1].  
 
1.3 The Importance of Chiral Analysis 
Most compounds in the amphetamine class contain a chiral center.  This means that 
these molecules contain a carbon atom that has four different substituents attached to it, 
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which causes the formation of two enantiomers, a dextro (d- or (+)) form and a levo (l- or 
(-)) form.  This refers to the direction that plane-polarized light is rotated when it passes 
through the molecule.  If a mixture contains both d-(+) and l-(-) forms, it is called racemic 
and the symbol ± is used to describe it.  Chiral molecules can also be referred to by the 
nomenclature S- or R-, a system in which the four substituents attached to the chiral carbon 
are assigned a priority based on atomic number and described whether the priority 
decreases moving clockwise or counterclockwise.  The d-form doesn’t necessarily 
correspond to S- for all compounds; it depends on the individual structure.  However, for 
the amphetamine class, the d-form and the S- form are equivalent, as are the l-form and the 
R-form.  S- and R- will be the terminology used throughout the rest of this paper. 
The formation of these enantiomers causes them to interact with the body in 
different ways, which affects their controlled status in the United States.  MDA and 
MDMA are classified as Schedule I substances under the Controlled Substances Act and 
although they contain chiral centers, neither enantiomer is legal for use in the United States 
[5].  
Despite the similarity between amphetamine and methamphetamine, the S- and R- 
enantiomers display differing pharmacological effects with the S- enantiomer producing a 
stronger, longer-lasting effect than the R- enantiomer.  R-methamphetamine has less 
stimulation properties than S-methamphetamine, but greater peripheral vasoconstrictive 
properties.  Because of this, the R- enantiomer has been attributed to some therapeutic uses, 
with R-methamphetamine used in some over-the-counter nasal decongestant products (e.g. 
Vicks® vapor inhaler).  When both enantiomers are present, the proportion of the R- to S- 
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enantiomer can aid in determining the source of the drug.  A racemic mixture is generally 
consistent with an illicit source, as is the exclusive presence of the S-enantiomer [11].  This 
is true with regards to amphetamine as well.  For example, a proportion of approximately 
1:3 R:S-amphetamine is indicative of a prescription source, such as Adderall® [12].  
In addition to direct usage, both R- and S-methamphetamine and R- and S- 
amphetamine can be seen as the metabolites of drugs used to treat pain and other disease 
states, which can further complicate interpretation.  Chan et al has reported finding 
methamphetamine consisting of approximately 68-78% the R-enantiomer and 
amphetamine consisting of approximately 51-59% the R-enantiomer in urine following the 
administration of the drug famprofazone [13].  
The ability to determine both the presence and chiral composition of amphetamine-
class compounds is an important tool in forensic analysis for interpreting results and 
suggesting the legality or illegality of amphetamine drug use.  The analysis of enantiomeric 
compounds has been successfully performed through a variety of non-chiral methods, such 
as gas chromatography (GC), liquid chromatography (LC), and nuclear magnetic 
resonance (NMR) [14-16].  However, these techniques are not selective enough to separate 
the enantiomers from each other.  In order to do so, further analysis must be performed. 
 
1.4 Traditional Chiral Analysis 
The chiral analysis of compounds has been carried out in a variety of ways.  Capillary 
electrophoresis, supercritical fluid chromatography, and immunoaffinity columns in 
conjunction with liquid chromatography-mass spectrometry (LC-MS) have all been used 
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to separate out chiral compounds, but derivatization remains the most common technique 
[17-18].  
Derivatization occurs when a compound is chemically changed to produce a new 
compound that is more amenable for a particular analysis.  It can be used to make thermally 
labile compounds more stable for GC analysis, but for chiral compounds, it is used to create 
molecules that are capable of being separated by a non-chiral method. 
Chiral derivatization works by transforming a pair of enantiomers into a pair of 
derivatized diastereomers by covalently reacting them with a homochiral reagent [19].  The 
resultant diastereomers should then have sufficiently differing chemical properties, and 
thus can be separated on a non-chiral column.  There are several factors that must be taken 
into consideration when selecting an effective derivatizing reagent, such as the distance 
between the chiral centers in the newly formed diastereomers, the conformation of the 
diastereomers, and the formation of possible hydrogen bonds [19]. 
Due to these factors, and taking the compound being derivatized and the method of 
analysis into consideration, there are a wide variety of derivatizing agents to choose from.   
This is true of the amphetamine class as well.  For example, l-N-trifluoroacetyl-prolyl 
chloride (TPC) has been used to derivatize amphetamine and methamphetamine for GC 
analysis [20-21].  Amphetamine and methamphetamine have both also been derivatized 
using 1-fluoro-2,4-dinitrophenyl-5-l-alanineamide, more commonly called Marfey’s 
reagent [22].  MDA and MDMA have been derivatized with N-(2,4-dinitro-5-
fluorophenyl) l-valinamide (DNPV) [17].  Amphetamine, methamphetamine, MDA, and 
MDMA are all capable of being derivatized by R-(-)-α-methoxy-α-
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(trifluoromethy)phenylacetyl chloride (MTPA) [23].  However, some studies have shown 
that, depending on the derivatizing agent, quantitation errors from 8-19% can occur when 
calculating against known standards [20].  
An additional issue with derivatization is the workup required, which could be an 
issue for a high-throughput laboratory.  Derivatization generally involves heating the 
sample with the derivatizing agent for a certain period of time, and then cooling the reaction 
back to room temperature before further analysis, with the necessary time varying by 
derivatizing agent.  For example, TPC requires a 15-minute incubation time, DNPV 
requires a 30-minute incubation time, and MTPA and Marfey’s reagent require an hour to 
properly derivatize compounds [20, 22, 23].  Cooke et al has a method which involves 
heating a sample with TPC for 10 minutes at 85-90°C, but it requires some workup after 
the mixture has cooled to remove any unreacted TPC [21].  
 
1.5 Chiral Column Chromatography 
To overcome the challenges associated with derivatization, chiral chromatography 
has emerged in recent years as a quicker and more accurate alternative.  Chiral 
chromatography utilizes a liquid chromatography column with a stationary phase that is 
capable of separating enantiomers.  Five types of chiral stationary phases have been used 
in liquid chromatography; they are polymer-based carbohydrates, Pirkle phases, 
cyclodextrins, chirobiotic phases, and protein-based phases [24].  Vancomycin, a form of 
chirobiotic stationary phase, and cyclodextrin have both been successfully used to separate 
chiral amphetamine compounds [18, 21, 25].  
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Regardless of the type of stationary phase used, the enantiomeric separation operates 
under similar principles.  Enantiomers are separated based on their differential ability to 
interact with the stationary phase in question, forming complexes through hydrogen 
bonding, π-π interactions, dipole stacking, inclusion complexing, and steric bulk [26].  At 
least three simultaneous interactions between the stationary phase and the analyte in 
question are required in order to cause enantiomeric separation in what is called the “three-
point rule” [27]. 
 
1.6 Research Objectives 
This research was done in conjunction with, and performed at, the San Francisco 
Office of the Chief Medical Examiner. The aim of this project was to develop and validate 
a method that separates and quantitates the enantiomers of amphetamines in blood utilizing 
liquid chromatography-tandem mass spectrometry.  The validation was performed 
according to the standards set forth by the Scientific Working Group for Forensic 
Toxicology (SWGTOX) [2].  Though SWGTOX is now a subcommittee of the 
Organization of Scientific Area Committees (OSAC) for Forensic Science, a newer 
document regarding method validation has yet to be published by OSAC.  The chiral 
separation was achieved using the novel Phenomenex Lux AMP® column, which is a new 
chiral column marketed to separate the enantiomers in the amphetamine class.  The 
compounds of interest are 1S,2R-ephedrine (EPH), 1R,2S-ephedrine, R-amphetamine 
(AMP), S-amphetamine, R-methamphetamine (MA), S-methamphetamine, racemic R/S-
MDA, racemic R/S-MDMA, and phentermine (PHE). The validation parameters include 
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linearity, limit of detection, limit of quantitation, processed sample stability, matrix effects, 
precision, bias, interference, and carryover studies. The final goal of the method was to 
analyze both postmortem biological samples from medical examiner casework and 
antemortem samples from driving under the influence casework at the San Francisco Office 
of the Chief Medical Examiner, with the intention of the forensic toxicology laboratory to 
utilize this method in authentic future forensic casework. 
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Analyte R1 R2 R3 R4 R5 R6 
1S,2R-Ephedrine  H OH H CH3 CH3 H 
1R,2S-Ephedrine  OH H CH3 H CH3 H 
R-Amphetamine  H H H CH3 H H 
S-Amphetamine H H CH3 H H H 
R-Methamphetamine H H H CH3 CH3 H 
S-Methamphetamine H H CH3 H CH3 H 
Phentermine H H CH3 CH3 H H 
R-MDA H H H CH3 H 3,4-methylenedioxy 
S-MDA H H CH3 H H 3,4-methylenedioxy 
R-MDMA H H H CH3 CH3 3,4-methylenedioxy 
S-MDMA H H CH3 H CH3 3,4-methylenedioxy 
Figure 1.  Chemical structures of targeted analytes.  The generic amphetamine structure was 
drawn using PubChem Sketcher V2.4 software.  
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2. MATERIALS AND METHODS 
2.1 Theory of Instrumentation 
2.1.1 Liquid Chromatography 
Liquid chromatography is a technique that is used in toxicological analysis as a way 
to separate out mixtures into their individual components.  It is based on the components’ 
individual affinities for a solid stationary phase coating the inside of an analytical column 
and a liquid mobile phase.  The different molecules in the mixture will adhere to the surface 
of the stationary phase with varying strengths depending on the polarity, causing the 
different components to exit the column at different times.  Molecules that have a weak 
affinity for the stationary phase will continue through the column quickly, whereas 
molecules with a strong affinity for the stationary phase will take longer to pass through 
the column. 
Liquid chromatography systems can be run in either normal phase or reversed phase 
mode.  In normal phase, the stationary phase is more polar than the mobile phase, causing 
polar compounds to elute from the column later.  In reversed phase, the mobile phase is 
more polar than the stationary phase, causing polar compounds to elute sooner.  Forensic 
toxicological analysis generally uses reversed phase liquid chromatography, with the 
mobile phase consisting of a mixture of an aqueous buffer and an organic solvent [3].  The 
composition and gradient of the mobile phase are factors in how the separation occurs.  
Other factors that can affect the separation include the temperature of the column and the 
flow rate.  
12 
 Once the compounds elute from the column, they must be detected.  Many 
molecules exhibit UV-vis absorption, so a UV-vis detector is one type of detector that has 
been used with LC systems.  Other detectors include fluorescence detectors, differential 
refractive index detectors, and evaporative light-scattering detectors.  By far, however, 
mass spectrometers are the detectors mostly used in forensics work, as they yield structural 
information about the compounds eluting from the column [3].  
Once detected, the results are then displayed in a chromatogram, which is a chart 
that shows the intensity on the y-axis and the time on the x-axis.  Each compound in the 
mixture is then visible as a peak on the chromatogram.  
 
2.1.2 Mass Spectrometry 
Mass spectrometry (MS) is an identification technique that involves the ionization 
and fragmentation of sample molecules into different patterns that can be used to elucidate 
structural information.  It is most often used in conjugation with GC or LC systems and 
involves charging analytes via an ionization source, separating them based on their mass-
to-charge (m/z) ratios to aid their detection.  The fragment ions are then displayed on a 
graph called a spectrum, which shows the intensity of each ion versus the m/z ratio.  
There are a variety of ionization sources available.  Chemical and electron 
ionization are commonly used for GC analysis, whereas electrospray ionization and 
atmospheric pressure chemical ionization are typical sources used for LC analysis.  The 
different ion sources vary in how much fragmentation they cause; electron ionization 
causes a lot of fragmentation to reveal more information about the structure of the 
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molecule.  Chemical ionization, on the other hand, is a “soft” ionization technique that 
reveals molecular mass information rather than structural information [28].    
There are also a variety of mass analyzers available, ranging from time-of-flight, 
ion trap, and quadrupole mass analyzers.  These analyzers vary in how ions are separated, 
as well as the transmission, upper mass range, and resolution of the analyzer [3].  Time-of-
flight mass analyzers separate ions based on the time it takes for ions to drift through a 
field-free flight tube.  Ion trap utilizes a ring electrode that subjects ions to a radiofrequency 
voltage with constant frequency but varying amplitude to eject ions of higher m/z for a full 
mass scan.  Quadrupoles consist of four rods in parallel that alternate between 
radiofrequency and direct current voltages to create an oscillating electric field that only 
allows certain ions though to the detector [3].   
Throughout the whole process, the mass spectrometer is under a vacuum.  This 
accomplishes a dual purpose; it directs the ions through the mass analyzer to the detector 
and also prevents unwanted collisions between the different ions that can lead to further 
uncontrolled fragmentation that would make a mass spectrum more difficult to interpret.  
Tandem mass spectrometry (MS/MS) is an additional form of mass spectrometry 
in which there are two separate stages of mass analysis.  The extra analyzer increases 
resolution and helps remove background matrix information so that only ions that are from 
the analyte of interest are visible in the mass spectrum.  Ion trap analyzers can be used for 
“tandem in time” mass spectrometry, in which selection of the ion of interest, 
fragmentation, and collection of the resulting ions are all contained within a single ion trap.  
Utilized in this project was a form of tandem mass spectrometry called triple quadrupole 
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mass spectrometry, sometimes referred to as “tandem in space” mass spectrometry, in 
which there are three physical sets of quadrupoles that the ions move through.  [3]. 
 
2.1.3 Multiple Reaction Monitoring 
 Multiple Reaction Monitoring (MRM) is a mode of operation used in mass 
spectrometry to increase the sensitivity of a particular method.  It is operated with a triple 
quadrupole tandem mass spectrometer and is especially useful for multi-analyte 
quantitative analyses to reduce the effects that matrices may have [29].  
In the instrument, the first quadruple selects a precursor ion with a specific m/z and 
allows it to move into the second quadrupole that acts as a collision cell to induce 
fragmentation of the precursor ion.  The fragmented ions then move into the third 
quadrupole and certain selected product ions from the collision cell in the second 
quadrupole are transmitted to the detector [29].  Essentially, the instrument looks for certain 
precursor ions, then fragments them into product ions, allowing for increased selectivity.   
Molecules are then identified through the specific combination of precursor and product 
ion ratios. 
 Instrument manufacturers have developed a specialized form of MRM called 
dynamic multiple reaction monitoring (dMRM) or scheduled multiple reaction monitoring 
(sMRM).  Instead of searching for selected precursor ions throughout an entire analytical 
run, the instrument is programmed to only search for precursor ions during a specific 
retention time window during which known compounds will elute from the LC or GC 
column.  By only searching for particular precursor ions during these relevant retention 
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time windows, the number of MRM transitions in each MS scan is reduced, allowing the 
method to use a longer dwell time and reduce the overall time for each MRM scan.  This 
results in greater response per data point and more data points per peak, increasing the 
sensitivity and precision of the method, respectively [29].  
 
2.2 Materials 
2.2.1 Standards and Reagents 
Standard methanolic solutions of 1 mg/mL of 1S,2R-ephedrine, 1R,2S-ephedrine, 
R-amphetamine, S-amphetamine, R-methamphetamine, S-methamphetamine, 
phentermine, ±MDA, and ±MDMA,  as well as deuterated internal standards of 100 µg/mL 
of 1S,2R-ephedrine-d3, ±amphetamine-d5, phentermine-d5, ±MDA-d5, and  ±MDMA-d5, 
were purchased from Cerilliant (Round Rock, TX, USA).  Butyl chloride and HPLC-grade 
methanol were purchased from Fisher Scientific (Pittsburgh, PA, USA).  Ammonium 
formate was purchased from Optima Chemical (Douglas, GA, USA).  Trizma buffer and 
ammonium hydroxide were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
Deionized water was purified using a Milli-Q Direct 8 system (EMD Millipore, Billerica, 
MA, USA).  
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Table 1.  Lot numbers of certified reference standards. All certified reference standards 
were obtained from Cerilliant and stored at -20°C. 
 
Standard Lot Number 
1S,2R-Ephedrine FN08281501 
1S,2R-Ephedrine-d3 FE07081402 
1R,2S-Ephedrine FE01121601 
R-Amphetamine FE03251601 
S-Amphetamine FE01261601 
±Amphetamine-d5 FE11111502 
R-Methamphetamine FE01191601 
S-Methamphetamine FE12181404 
Phentermine FE09231511 
Phentermine-d5 FE060412-04 
±MDA FE11121503 
±MDA-d5 FE01131506 
±MDMA FE01121502 
±MDMA-d5 FE04221406 
 
2.2.2 Liquid Chromatograph-Tandem Mass Spectrometer  
 The chromatographic system was an Agilent 1260 series liquid chromatograph 
(Agilent Technologies, Santa Clara, CA, USA) fitted with a Phenomenex Lux AMP® 
column and guard column (3 µm, 150 x 3.0 mm, Phenomenex, Torrance, CA, USA).  The 
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targets were detected using an Agilent 6460 series triple quadrupole mass spectrometer 
with electrospray ionization (Agilent Technologies, Santa Clara, CA, USA). 
The instrument was operated with the Agilent MassHunter data acquisition 
software (version B.07.01) and the data was processed using the Qualitative Analysis 
(version B.07.00) and Quantitative Analysis (version B.07.00) software (Agilent 
Technologies, Santa Clara, CA, USA).  Additional statistical analysis was performed using 
Excel (Microsoft Corporation, Redmond, WA, USA).  
 
2.3 Methods 
2.3.1 Preparation of Stock Solutions 
 Stock solutions of the certified reference standards contained 1.0 mg/mL 
concentrations.  Three working stock solutions were prepared combining all analytes to 
prepare calibrators.  Working solution 1 was diluted in methanol from the stock solutions 
to create a 100 µg/mL solution.  Working solution 1 was further diluted in methanol to 
make a 10 µg/mL solution (Working solution 2).  Working solution 2 was further diluted 
in methanol to make a 1 µg/mL solution (Working solution 3).  The stocks and working 
solutions were then diluted to create stock solutions at the following concentrations for use 
as calibrator and quality controls and for LOD studies: 1, 2, 5, 10, 25, 50, 75, 100, 250, 
300, 500, and 1000 µg/L.   
The internal standard stocks were purchased in 100 µg/mL concentrations.  The 
internal standards were combined and diluted to contain 100 µg/L of each internal standard 
in a single internal standard stock solution.  
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2.3.2 Liquid-Liquid Extraction 
 Liquid-liquid extraction was performed as the sample preparatory technique.  
Extraction of the target analytes from the 200 µL of blood was performed by the addition 
of 10 µL of the internal standard solution and, if required, 10 µL of the appropriate 
calibration solution. To this, 300 µL of 2M Trizma buffer (pH 9.2) was added and 
following brief vortex mixing, 1000 µL of n-butyl chloride was added.  The samples were 
then capped and placed for 5 min on a Talboys Multi-Tube Vortexer (Troemner, Atkinson, 
NH, USA).  After centrifugation for 2 minutes at 16,163 g on a Microfuge® 16 (Beckman 
Coulter, Indianapolis IN, USA), 950 µL of the top organic layer was transferred to a 
champagne auto-sampler vial and gently evaporated to dryness under compressed air.  The 
samples were then reconstituted in 50 µL of methanol for LC-MS/MS analysis. 
 
2.3.3 Compound Optimization 
 The MRM mode data acquisition parameters for each analyte and internal standard 
were automatically optimized using the Agilent MassHunter Optimizer software (Agilent 
Technologies, Santa Clara, CA, USA).  Optimizer is a program that chooses the best mass 
spectrometry parameters for compounds.  This process was started by entering the chemical 
structure of each compound into the program to determine the starting mass.  Reference 
standards for each compound were diluted to a 100 µg/L concentration in methanol and 
injected into the mass spectrometer per the Optimizer program.  The fragmentor range was 
set from 25-100 volts.  The collision energy was set from 0-30 volts in positive ion mode.  
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For each compound, Optimizer selected the best precursor ions and product ions, and 
optimized the fragmentor voltage for each precursor ion and the collision energy values for 
each transition.  The data was then reviewed manually to confirm that the abundance was 
sufficient to use in this method.  
Abundance of the phentermine-d5 and ±MDA-d5 internal standards during 
optimization was low and as such, they were not used in this method.  A MRM method 
was then created utilizing 1S,2R-ephedrine-d3, ±amphetamine-d5, and ±MDMA-d5 as the 
internal standards.  1S,2R-ephedrine-d3 was used as the internal standard for 1S,2R-
ephedrine and 1R,2S-ephedrine.  ±Amphetamine-d5 was used as the internal standard for 
R-amphetamine, S-amphetamine, R-methamphetamine, S-methamphetamine, and 
phentermine.  ±MDMA-d5 was used as the internal standard for MDA and MDMA.  
The racemic internal standards, ±amphetamine-d5 and ±MDMA-d5, each produced 
two internal standard peaks as the chiral column separated them into their respective 
enantiomers.  Only the first peak of each internal standard, designated AMP-d5-1 and 
MDMA-d5-1, respectively, was used for quantitation purposes.  
However, the amphetamine-d5 did not amplify well once it was used in the method 
and ultimately 1S,2R-ephedrine-d3 was chosen to quantify 1S,2R-ephedrine, 1R,2S-
ephedrine, R-amphetamine, S-amphetamine, R-methamphetamine, S-methamphetamine, 
and phentermine.  MDMA-d5-1 remained as the internal standard for MDA and MDMA.  
The standards of MDA and MDMA also produced two peaks as they were separated 
chirally due to the chiral column.  The first peak of each compound that eluted was 
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designated “MDA-1” and “MDMA-1”, respectively, and the second peak that eluted was 
designated “MDA-2” and “MDMA-2”.  
 
2.3.4 LC-MS/MS Parameters 
The LC-MS/MS parameters were determined from the previously described 
optimization.  After the method was developed, the most intense product ions were selected 
for each compound.  For the analytes, the most intense ion was selected as the quantitative 
ion and the second and third most intense ions were selected as qualitative ions for analyte 
confirmation.  Guidelines require only one qualitative ion; however, to increase selectivity, 
two were used for this analytical method.  For the internal standards, one quantitative and 
one qualitative ion were selected.  Table 2 shows the final MRM parameters used for all 
analyses.  The duration of the MRM scan was set for one minute above and one minute 
below the retention time for each analyte.  The mass spectrometer was operated in positive 
ion multiple reaction monitoring mode.  The source conditions were as follows: gas 
temperature, 300°C; gas flow, 5 L/min; nebulizer, 40 psi; capillary voltage, positive 3500 
V; dwell time, 200 ms. 
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Table 2.  The MRM parameters for all analytes 
 
Analyte Ions Precursor Ion  
(m/z) 
Product Ion  
(m/z) 
Fragmentor  
(V) 
Collision 
Energy  
(V) 
1S,2R-EPH Quant 
Qualifier 
Qualifier 
166.1 148.1 
133 
117 
94 8 
20 
20 
1R,2S-EPH Quant 
Qualifier 
Qualifier 
166.1 148.1 
133 
117 
91 8 
20 
20 
R-AM Quant 
Qualifier 
Qualifier 
136.1 119.1 
91 
65 
85 16 
4 
30 
S-AM Quant 
Qualifier 
Qualifier 
136.1 119.1 
91 
65 
85 12 
4 
30 
R-MA Quant 
Qualifier 
Qualifier 
150.1 91.2 
119 
65 
97 20 
8 
30 
S-MA Quant 
Qualifier 
Qualifier 
150.1 91.2 
119 
65 
94 20 
8 
30 
PHE Quant 
Qualifier 
Qualifier 
150.1 91.2 
133 
65 
82 20 
4 
30 
MDA-1 Quant 
Qualifier 
Qualifier 
180.1 163.0 
105 
135 
82 4 
24 
16 
MDA-2 Quant 
Qualifier 
Qualifier 
180.1 163.0 
105 
135 
82 4 
24 
16 
MDMA-1 Quant 
Qualifier 
Qualifier 
194.1 163.0 
105 
135 
94 8 
24 
20 
MDMA-2 Quant 
Qualifier 
Qualifier 
194.1 163.0 
105 
135 
94 8 
24 
20 
EPH-d3 Quant 
Qualifier 
169.1 151.1 
117 
54 8 
21 
MDMA-d5 Quant 
Qualifier 
Qualifier 
199.1 135.0 
165.0 
107 
106 8 
28 
20 
 
22 
Different mobile phases of varying pH and different flow rates were investigated 
to obtain the best separation for the LC.  The pKa of the target analytes are available in 
Table 3.  A table of the different LC parameters that attempted and discarded is available 
as Table A in Appendix A.  
 
Table 3.  The pKa of the target analytes. The compounds are listed without chiral 
distinction because chirality does not change the pKa.  
 
Compound pKa 
Ephedrine 9.65 
Amphetamine 10.1 
Methamphetamine 9.87 
Phentermine 10.1 
MDA 9.67 
MDMA 9.9 
 
The finalized method used 5mM ammonium formate buffer, adjusted to pH 11 
using ammonium hydroxide, as the aqueous phase (mobile phase A) and LC-grade 
methanol as the organic phase (mobile phase B).  The flow rate was set to 0.8 mL/min and 
the temperature of the column was set to 40°C.  The initial method starting conditions were 
set at 42% of mobile phase B.  After a 5 µL sample injection, the % B concentration 
increased over time, as shown in Table 4.  After 17.10 minutes, the % B returned to the 
42% starting condition and was held for 2 minutes during column re-equilibration. 
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Although the maximum pressure of the LC system is 600 bar, the maximum pressure 
achieved using the parameters set in this method was 350 bar. 
 
Table 4.  The LC mobile phase gradient. Solvent A is 5mM ammonium formate at pH 
11. Solvent B is methanol.  
 
Time (min) Solvent A (%) Solvent B (%) 
0.00 58.0 42.0 
0.30 58.0 42.0 
3.00 57.0 43.0 
3.10 50.0 50.0 
9.00 48.0 52.0 
9.10 43.0 57.0 
17.00 40.0 60.0 
17.10 58.0 42.0 
 
The autosampler was operated at 4°C and the autosampler needle was rinsed before 
and after aspiration of the sample using methanol to prevent cross-contamination.  
 
2.4 Validation 
The validation plan was based on the Scientific Working Group for Forensic 
Toxicology standards and internationally recommended guidelines [2, 30].  Validation 
criteria included limits of detection and quantitation, linearity, carryover, precision, bias, 
interferences, matrix effects, extraction recovery, and processed sample stability.  
 
2.4.1 Linearity 
The calibration model was developed in order to demonstrate a mathematical 
relationship between the analyte concentration and the corresponding instrument response.  
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This was done by first preparing blood samples at concentrations of 1, 2, 5, 10, 25, 50, 100, 
250, 500, and 1000 µg/L.  These samples were then extracted via liquid-liquid extraction, 
reconstituted in methanol, and run on the LC-MS/MS.  Once a calibration model was 
developed, the linearity was assessed by running all points in the working range five times 
over five separate days.  All analyte curves were visually checked for a linear or quadratic 
fit and weighting (none, 1/x, or 1/x2).  The calibration model was deemed acceptable if the 
coefficient of determination (R2) was at least 0.99.  Due to the racemic nature of the MDA 
and MDMA standards, a separate calibration curve was generated for those drugs in Excel 
combining the two enantiomers of those compounds to quantitate total MDA and total 
MDMA.  This curve was generated by calculating the relative response for each peak and 
adding the relative responses together, to plot against the concentration of racemic analyte 
that the sample was fortified with.  
 
2.4.2 Limits of Detection and Quantitation 
Once the calibration model was developed, the limit of detection (LOD) and lower 
limit of quantitation (LLOQ) was determined for each analyte.  The LOD is the lowest 
concentration of an analyte in a sample that can be reliably differentiated from a blank 
matrix and identified.  It was assessed as the lowest concentration analyzed with acceptable 
chromatography, three MRM transitions with acceptable ion ratios, and signal-to-noise 
ratios of at least 3:1.  The LOD was assessed from spiked blank matrix samples from three 
different sources over three runs. 
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The LLOQ is the lowest concentration of an analyte in a sample that can be reliably 
measured with acceptable precision and accuracy.  It was assessed as the lowest 
concentration analyzed with acceptable chromatography, three MRM transitions with 
acceptable ion ratios, signal-to-noise ratios of at least 10:1, and acceptable precision and 
bias.  The LOQ was assessed from spiked blank matrix samples from three different 
sources over three runs.  
 
2.4.3 Processed Sample Stability 
The stability of the extracted processed samples over 24 hours was investigated at 
two different concentrations.  Seven blank blood samples were fortified with analytes, 
extracted as normal, pooled and mixed, and then transferred to seven new autosampler vials 
and placed on the autosampler carousel at 4°C for 24 hours.  Low and high QC 
concentrations of 75 µg/L and 300 µg/L, respectively, were analyzed in triplicate every 
four hours over this time period and the peak areas compared.  The analytes were 
considered stable if the response remained within ±20% of the peak area at time zero (T0). 
 
2.4.4 Matrix Effects/Extraction Efficiency/Process Efficiency 
The effects of the blood matrix on ion suppression and enhancement was estimated, 
as well as the extraction efficiency of the liquid-liquid extraction and the overall process 
efficiency.  These were estimated with three sets of samples at two concentrations, the QC 
low concentration of 75 µg/L and the QC high concentration of 300 µg/L.  Sample set 1 
consisted of the neat standard in methanol and was injected six times to obtain an average.  
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Sample set 2 consisted of ten blank matrix samples from ten different sources (5 
antemortem and 5 postmortem) that were extracted and then fortified with the appropriate 
concentration of analyte post-extraction.  Sample set 3 consisted of five of the blank matrix 
samples used in sample set 2; however, this set was fortified with an appropriate 
concentration of analyte pre-extraction. The ten blank samples were screened prior to the 
study via the laboratory’s non-chiral method to ensure no amphetamines were present. 
The ion suppression or enchantment effects of the matrix were estimated by 
comparison of the peak area of the samples of set 2, the samples spiked post-extraction, to 
the average peak area of set 1, the neat standards. 
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Extraction efficiencies were estimated by comparison of the peak area of the 
samples of set 3, the samples spiked pre-extraction, to the average peak area of set 2, the 
samples spiked post-extraction.   
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Process efficiencies were estimated by comparison of the peak area of the samples 
of set 3, the samples spiked pre-extraction, to the average peak area of set 1, the neat 
standards.  This equation is a simplified calculation that takes the equation for extraction 
efficiency and multiplies it by the equation for the matrix effects.  By doing so, the process 
efficiencies can calculate the recovery while taking matrix effects into consideration [30].   
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All figures are represented as a percentage.  General acceptability levels of 50% 
extraction efficiency or more were applied.  Values over 100% for matrix effects indicate 
ion enhancement, while values below 100% indicate ion suppression.  
 
2.4.5 Precision and Bias 
Precision and bias studies were performed to estimate the accuracy and 
reproducibility of the method.  Precision and bias were assessed by running pooled matrix 
samples from three different blank blood sources at a near-LLOQ concentration (25 µg/L), 
medium (300 µg/L), and high (800 µg/L) analyte concentrations in triplicate over five runs 
on different days.  All samples were extracted and analyzed under the developed method.  
The maximum acceptable bias is ±20% at all three concentrations.  For low concentrations, 
the precision acceptance limit was set to ±20% relative standard deviation (RSD).  For 
medium and high concentrations, the precision acceptance limit was set to ±15% RSD [31].  
 
2.4.6 Interferences 
Potential interferences from matrix sources, internal standards, and other common 
drugs were evaluated.  Potential matrix interferences were evaluated by running five blank 
postmortem and five blank antemortem blood samples obtained by the laboratory for 
routine toxicological requirements. The ten different blood samples were extracted and 
analyzed to demonstrate any interference with targeted ions from endogenous compounds.  
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Potential interferences from the deuterated internal standards due to impurities of the 
pure drug, in vitro conversion to target analytes during the methodological process, or 
potential crosstalk of ions within the MS, were evaluated by spiking three blank blood 
samples with solely the internal standards. 
Additionally, the same potential interferences from commonly encountered drugs or 
metabolites were evaluated by fortifying three blank matrix samples with toxic and lethal 
high concentrations of the following compounds: 6-monoacetylmorphine, 7-
aminoclonazepam, 7-aminoflunitrazepam, 7-aminonitrazepam, alfentanil, alprazolam, 
amitriptyline, anhydroecgonine methyl ester, baclofen, barbital, benzoylecgonine, 
bromazepam, buprenorphine, bupropion, butorphanol, cannabidiol, chlordiazepoxide, 
chlorpheniramine, citalopram, clobazam, clonazepam, clonidine, cocaethylene, cocaine, 
codeine, cyclobenzaprine, desipramine, desmethylcitalopram, dextromethorphan, 
diazepam, digoxin, dihydrocodeine, diltiazem, diphenhydramine, doxepin, doxylamine, 2-
ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine, fentanyl, flunitrazepam, fluoxetine, 
flurazepam, gabapentin, hydrocodone, hydromorphone, hydroxyzine, JWH-018, ketamine, 
lidocaine, lorazepam, lormetazepam, meprobamate, methadone, methylphenidate, 
midazolam, mirtazapine, morphine, nitrazepam, nordiazepam, norfentanyl, norfluoxetine, 
norketamine, norpropoxyphene, strychnine, norsertraline, nortriptyline, olanzapine, 
oxazepam, oxycodone, paroxetine, phenazepam, promethazine, quetiapine, sertraline, 
temazepam, tramadol, trazodone, triazolam, UR-144, venlafaxine, zolpidem, ɑ-hydroxy 
alprazolam, ɑ-hydroxy triazolam, 11-nor-9-carboxy-∆-9-tetrahydrocannabinol, 11-
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hydroxy-∆-9-tetrahydrocannabinol, and ∆-9-tetrahydrocannabinol. Acceptable selectivity 
was determined if the interfering compounds, if present, were below 10% of the LODs.  
 
2.4.7 Carryover 
Carryover was assessed by the assessment of a methanol blank directly after the 
highest concentration calibrator to determine that no target analytes remained in the 
analytical system.  This was performed in triplicate.  Lack of carryover was established if 
the analyte concentrations in the blank were below 10% of the LODs.  
 
2.5 Applicability to Authentic Casework 
 Twenty-eight cases from the San Francisco Office of the Chief Medical Examiner 
that had previously been analyzed via a non-chiral method were analyzed utilizing the 
method developed here as proof of method.  To achieve anonymity, the cases were 
designated new numbers from 1-28, rather than their original case numbers.  Five cases 
had previously been quantitated with concentrations above the linear range of this method; 
these cases were diluted prior to extraction.  The cases were reviewed by another 
toxicologist and assigned dilution factors, as necessary.  Case 1 was assigned a dilution 
factor of 2, Case 5 a dilution factor of 2, Case 19 a dilution factor of 5, Case 24 a dilution 
factor of 20, and Case 28 a dilution factor of 4.  Other than the dilution factor, all case 
studies were performed as a blind test, with no knowledge of the outcome.  The samples 
were extracted and analyzed via the liquid-liquid extraction method detailed previously.  
During the same analysis, QC low (75 µg/L) and QC high (300 µg/L) samples, a set of 
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calibrators ranging from 10-1000 µg/L, and a negative control from certified blank blood, 
were simultaneously extracted.  Results were interpreted prior to comparison with the case 
records.  
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3. RESULTS 
3.1 Detection of Analytes 
 A methanol blank was run before any samples to allow for the pressure to 
equilibrate in order to keep the analyte retention times consistent.  After injection, there is 
a 0.5-minute hold period during which the mobile phase B is maintained at 42%.  This 
allows analytes to interact with the stationary phase of the column prior to elution.  Similar 
analytes will pass through the column more closely together, testing the ability of the 
column to resolve the enantiomers selectively [32].  
Following the elution of all analytes within 15 minutes, there was a 2-minute re-
equilibration time in order to ensure that the starting conditions were reproducible between 
injections. The analytes eluted in the following order: 1S,2R-ephedrine at 3.1 minutes; 
1R,2S-ephedrine at 3.5 minutes; R-amphetamine at 5.7 minutes; S-amphetamine at 6.2 
minutes; R-methamphetamine at 6.6 minutes; S-methamphetamine at 7.1 minutes; 
phentermine at 8.9 minutes; MDMA-1 at 11.8 minutes; MDA-1 at 12.7 minutes; MDA-2 
at 13.8 minutes; and MDMA-2 at 14.0 minutes.  The internal standards elute in the 
following order at the following times: 1S,2R-ephedrine-d3 at 3.0 minutes and MDMA-
d5-1 at 11.7 minutes.  
Neither 1S,2R-ephedrine and 1R,2S-ephedrine nor R-methamphetamine and S-
methamphetamine could be resolved at baseline, however there was some separation 
providing selective identification between these enantiomers.  There was some overlap 
between the MDA and MDMA peaks, but they are resolved through the different mass 
spectrometry precursor ions and MRM transitions.  
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Figure 2.  Extracted ion chromatogram of QC low (75 µg/L) in blood. Analytes elute 
at the following retention times and in the following order: 1S,2R-EPH-d3 at 3.0 min; 
1S,2R-EPH at 3.1 min; 1R,2S-EPH at 3.5 min; R-AMP at 5.7 min; S-AMP at 6.2 min; R-
MA at 6.6 min; S-MA at 7.1 min; PHE at 8.9 min; MDMA-d5-1 at 11.7 min; MDMA-1 at 
11.8 min; MDA-1 at 12.7 min; MDA-2 at 13.8 min; and MDMA-2 at 14.0 min.  
 
 
3.2 Validation 
3.2.1 Linearity 
Although calibrators ranging from 1-1000 µg/L were tested, the working range was 
from 10-1000 µg/L. Seven calibration points (10, 25, 50, 100, 250, 500, and 1000 µg/L) 
were used and the regression was linear without any weighting.  
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Figure 3.  Examples of the linear calibration curve for all analytes extracted from 
blood 
 
Table 5.  Calibration equations and coefficient determination values for the example 
curves shown in Figure 3 
 
Analyte Equation R
2
 value 
1S,2R-Ephedrine y = 1.6277x - 6.5086 0.9976 
1R,2S-Ephedrine y = 0.4871x - 2.7011 0.9998 
S-Amphetamine y = 0.0866x - 0.984 0.9931 
R-Amphetamine y = 0.1321x - 0.6212 0.9978 
S-Methamphetamine y = 1.6277x - 6.5086 0.9976 
R-Methamphetamine y = 0.9174x - 9.7383 0.9976 
Phentermine y = 0.0858x - 0.468 0.9992 
MDMA y = 0.4782x - 3.4428 0.9948 
MDA y = 0.3296x - 0.2257 0.9977 
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3.2.2 Limits of Detection and Quantitation 
The LOD was determined to be 2 µg/L for 1S,2R-ephedrine, 1R,2S-ephedrine, R-
amphetamine, S-amphetamine, R-methamphetamine, S-methamphetamine, and 
phentermine, and 10 µg/L for MDMA and MDA.  
The LLOQ was determined to be 10 µg/L for all compounds. 
 
3.2.3 Processed Sample Stability 
Over the course of 24 hours, the QC low value peak area ranges were as follows: 
1S,2R-ephedrine ranged from 110%-124%; 1R,2S-ephedrine ranged from 101-123%; R-
amphetamine ranged from 85%-109%; S-amphetamine ranged from 106-114%; R-
methamphetamine ranged from 101-103%; S-methamphetamine ranged from 100-103%; 
phentermine ranged from 101-105%; MDMA-1 ranged from 94%-102%; MDMA-2 
ranged from 94-102%; MDA-1 ranged from 83%-102%; and MDA-2 ranged from 85%-
108%.  This is represented graphically in Figure 4.  Only 1S,2R-ephedrine and 1R,2S-
ephedrine were outside the expected ±20% occurring after approximately 16 hours.  
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Figure 4.  Low QC stability study results. The results of the stability study for all analytes 
over the course of 24 hours with a concentration of 75 µg/L. All results are shown as a 
percentage of the peak area at T0. 
  
Over the course of 24 hours, the QC high value peak area ranges were as follows: 
1S,2R-ephedrine ranged from 111%-134%; 1R,2S-ephedrine ranged from 104%-135%; R-
amphetamine ranged from 103%-131%; S-amphetamine ranged from 108%-120%; R-
methamphetamine ranged from 103%-106%; S-methamphetamine ranged from 104%-
108%; phentermine ranged from 104%-111%; MDMA-1 ranged from 99%-108%; 
MDMA-2 ranged from 98%-110%; MDA-1 ranged from 85%-111%; and MDA-2 ranged 
from 99%-110%.  This is represented graphically in Figure 5.  1S,2R-ephedrine, 1R,2S-
ephedrine, and R-amphetamine were outside the expected ±20% occurring after 
approximately 12 and 16 hours, respectively.  
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Figure 5.  High QC stability study results. The results of the stability study for all 
analytes over the course of 24 hours with a concentration of 300 µg/L. All results are shown 
as a percentage of the peak area at T0.  
 
 
 
3.2.4 Matrix Effects/Extraction Efficiency/Process Efficiency 
The average matrix effects, extraction efficiency, and process efficiency results are 
shown in Table 6.  
The range of matrix effects for the QC low concentration over the ten post-
extraction fortified samples were as follows: 1S,2R-ephedrine ranged from 216%-313%; 
1R,2S-ephedrine ranged from 219%-318%; R-amphetamine ranged from 228%-340%; S-
amphetamine ranged from 237%-347%; R-methamphetamine ranged from 206%-302%; 
S-methamphetamine ranged from 217%-309%; phentermine ranged from 235%-334%; 
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MDMA-1 ranged from 208%-335%; MDMA-2 ranged from 204%-327%; MDA-1 ranged 
from 219%-346%; and MDA-2 ranged from 263%-433%. 
The range of matrix effects for the QC high concentrations over the ten post-
extraction fortified samples were as follows: 1S,2R-ephedrine ranged from 131%-146%; 
1R,2S-ephedrine ranged from 140%-165%; R-amphetamine ranged from 144%-200%; S-
amphetamine ranged from 160%-203%; R-methamphetamine ranged from 134%-148%; 
S-methamphetamine ranged from 140%-163%; phentermine ranged from 169%-220%; 
MDMA-1 ranged from 157%-214%; MDMA-2 ranged from 127%-192%; MDA-1 ranged 
from 149%-228%; and MDA-2 ranged from 170%-270%.  
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Table 6.  The average matrix effects, extraction efficiency, and process efficiency for 
all analytes at low (75 µg/L) and high (300 µg/L) QC concentrations 
 
Analyte Matrix Effect 
%, (% RSD) 
Extraction Efficiency Process Efficiency 
 QC Low QC High QC Low QC High QC Low QC 
High 
1S-2R EPH 280%, 
(10.8%) 
140%, 
(3.0%) 
68% 75% 189% 105% 
1R,2S-EPH 283%, 
(11.0%) 
149%, 
(5.7%) 
69% 73% 196% 109% 
R-AMP 298%, 
(11.8%) 
173%, 
(9.8%) 
101% 83% 297% 144% 
S-AMP 306%, 
(11.2%) 
183%, 
(7.3%) 
105% 66% 321% 121% 
R-MA 267%, 
(10.5%) 
140%, 
(3.2%) 
123% 108% 329% 151% 
S-MA 271%, 
(10.8%) 
152%, 
(4.4%) 
116% 98% 315% 122% 
PHE 299%, 
(10.8%) 
200%, 
(8.0%) 
120% 87% 359% 174% 
MDMA-1 296%, 
(13.0%) 
188%, 
(9.1%) 
109% 83% 323% 157% 
MDMA-2 285%, 
(12.1%) 
161%, 
(10.6%) 
104% 85% 296% 137% 
MDA-1 308%, 
(11.9%) 
195%, 
(12.3%) 
96% 60% 294% 118% 
MDA-2 361%,  
(7.0%) 
229%, 
(13.8%) 
118% 66% 432% 152% 
 
3.2.5 Precision and Bias 
Generally, acceptable precision should be within 15% for medium and high 
concentrations and within 20% for low concentrations.  All analytes achieved acceptable 
precision, with 13.0% as the maximum precision value reached for MDMA-2. 
According to SWGTOX standards, the bias results should be within ±20% for all 
analytes at all concentrations [2].  All analytes, except 1S,2R-ephedrine and both MDA 
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enantiomers, had at least one concentration level fall outside the ±20% bias range. The 
results can be seen in Table 7.  
 
Table 7.  Bias and between-run precision results for all analytes at low (25 µg/L), 
medium (300 µg/L), and high (800 µg/L) concentrations 
 
Analyte Bias (%) Precision (% RSD) 
 Low Med High Low Med High 
1S-2R EPH -0.3% -17.7% -12.5% 3.3% 3.2% 5.5% 
1R,2S-EPH 9.9% -24.2% -14.6% 2.9% 3.2% 4.9% 
R-AMP -25.3% -25.3% -9.5% 6.3% 4.0% 6.5% 
S-AMP -27.9% -14.9% -27.0% 9.2% 4.4% 7.4% 
R-MA 10.4% -27.3% -8.8% 4.1% 3.8% 8.2% 
S-MA -5.3% -28.4% -24.2% 4.5% 3.8% 6.2% 
PHE -1.9% -31.5% -25.6% 3.5% 4.0% 6.9% 
MDMA-1 32.1% -14.8% -7.5% 3.0% 3.0% 7.7% 
MDMA-2 103.4% 34.5% 81.0% 8.9% 6.6% 13.0% 
MDA-1 6.1% -18.0% -17.1% 5.1% 2.7% 8.2% 
MDA-2 -14.3% -12.9% -11.8% 9.4% 3.5% 8.4% 
 
3.2.6 Interferences 
Interferences, selectivity, and crosstalk investigations showed no indication that 
antemortem blood, postmortem blood, internal standards, or other common therapeutic and 
illicit drugs caused interferences with the analytical method. 
 
3.2.7 Carryover 
 There was no indication of carryover when assessing the blanks run after samples 
containing 1000 µg/L of all analytes over repeated analyses. 
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3.3 Applicability to Authentic Casework 
The calibration curve that was run with the case samples failed to correspond to a 
linear trend line and as such, quantification and comparison to the case samples was not 
possible for most analytes.  The exception to this is MDA and MDMA; they were the only 
analytes with acceptable linearity and as such, they were the only analytes for which a 
quantitative comparison of the non-chiral and chiral methods was possible.  The other 
analytes were analyzed qualitatively to determine which enantiomer was present, though 
no concentrations could be determined.  The equations of the calibrators for each analyte 
and their R2 values when analyzed linearly can be seen in Table 8.  The quantitative results 
of comparison for MDA and MDMA can be seen in Table 9 and Table 10, and the 
qualitative results for all analytes can be seen in Table 11.  
 
Table 8.  Calibration equations and coefficient of determination values for the 
curves run with the cases 
 
Analyte Equation R
2
 Value 
1S,2R-Ephedrine y = 0.1705x + 17.116 0.9213 
1R,2S-Ephedrine y = 0.2375x + 17.65 0.9627 
R-Amphetamine y = 0.1535x + 11.303 0.9445 
S-Amphetamine y = 0.1474x + 11.166 0.9383 
R-Methamphetamine y = 0.1837x + 31.776 0.8838 
S-Methamphetamine y = 0.2892x + 40.944 0.8909 
Phentermine y = 0.0921x + 6.8628 0.9417 
MDMA y = 1.4693x + 34.808 0.996 
MDA y = 0.9082x + 18.902 0.9931 
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Table 9.  Quantitative comparison of MDA from case samples 
 
Case Non-chiral MDA concentration (µg/L) Chiral MDA concentration (µg/L) 
3 Not detected Below LOQ 
7 30 Below LOQ 
14 93 108 
23 12 Below LOQ 
25 Not detected Below LOQ 
28 Not detected 43 
 
 
 
Table 10.  Quantitative comparison of MDMA from case samples 
 
Case Non-chiral MDMA concentration (µg/L) Chiral MDMA concentration (µg/L) 
3 440 609 
14 1212 886 
23 130 169 
25 140 243 
28 4000 3094 
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Table 11.  Qualitative comparison of non-chiral and chiral results for the 28 cases 
 
Case Non-chiral Results Chiral LC-MS/MS Results 
1 Amphetamine; Methamphetamine S-Amphetamine; S-Methamphetamine 
2 Amphetamine; Methamphetamine S-Amphetamine; S-Methamphetamine 
3 Amphetamine; MDMA S-Amphetamine; MDA-1; MDA-2; MDMA-1; MDMA-
2 
4 Ephedrine; Amphetamine; 
Methamphetamine 
1R,2S-Ephedrine; S-Amphetamine; S-
Methamphetamine 
5 Amphetamine; Methamphetamine S-Amphetamine; S-Methamphetamine 
6 Phentermine Phentermine 
7 MDA MDA-1; MDA-2 
8 Ephedrine; Amphetamine; 
Methamphetamine 
R-Amphetamine; S-Amphetamine; S-Methamphetamine 
9 Amphetamine; Methamphetamine 1R,2S-Ephedrine; S-Amphetamine; S-
Methamphetamine 
10 Methamphetamine S-Amphetamine; S-Methamphetamine 
11 Phentermine Phentermine 
12 Amphetamine; Methamphetamine 1R,2S-Ephedrine; S-Amphetamine; S-
Methamphetamine 
13 Phentermine S-Amphetamine; S-Methamphetamine 
14 Methamphetamine; MDA; MDMA S-Amphetamine; S-Methamphetamine; MDA-1; MDA-
2; MDMA-1; MDMA-2 
15 Pseudoephedrine; 
Norpseudoephedrine 
Non-Ephedrine Peak 
16 Phentermine Phentermine 
17 Amphetamine; Methamphetamine 1R,2S-Ephedrine; S-Amphetamine; S-
Methamphetamine 
18 Amphetamine; Methamphetamine 1R,2S-Ephedrine; S-Amphetamine; S-
Methamphetamine 
19 Amphetamine; Methamphetamine 1R,2S-Ephedrine; S-Amphetamine; S-
Methamphetamine 
20 Amphetamine; Methamphetamine S-Amphetamine; S-Methamphetamine 
21 Ephedrine; Pseudoephedrine Non-Ephedrine peak 
22 Phentermine Phentermine 
23 MDA; MDMA MDA-1; MDA-2; MDMA-1; MDMA-2 
24 Amphetamine; Methamphetamine 1R,2S-Ephedrine; S-Amphetamine; S-
Methamphetamine 
25 MDMA MDA-2; MDMA-1; MDMA-2 
26 Phentermine; Methamphetamine Phentermine; S-Amphetamine; S-Methamphetamine 
27 Amphetamine; Methamphetamine S-Amphetamine; S-Methamphetamine 
28 Methamphetamine; MDMA 1R,2S-Ephedrine; S-Amphetamine; S-
Methamphetamine; MDA-1; MDA-2; MDMA-1; 
MDMA-2 
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 Small amounts of ephedrine were seen in Cases 9, 12, 17, 18, 19, 24, and 28, where 
it had not been detected prior.  Small amounts of amphetamine were seen in Cases 10, 14, 
26, and 28, where it had not been detected prior.  Small amounts of MDA were seen in 
Cases 3, 25, and 28, where it had not been detected prior.  
The term “non-ephedrine peak”, seen in Cases 15 and 21, designates a peak with 
the same ions as ephedrine, but in different ion ratios and at a different retention time.  Both 
Case 15 and Case 21 had the non-ephedrine peak elute at 3.7 minutes, as opposed to 3.5 
minutes.   
 Every methamphetamine enantiomer detected was the “S” enantiomer, as was 
every amphetamine enantiomer, with the exception of Case 8.  S-methamphetamine, S-
amphetamine, and a small amount of R-amphetamine was detected in Case 8.  
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4. DISCUSSION 
4.1 Detection of Analytes 
 The peaks of 1S,2R-ephedrine and 1R,2S-ephedrine were unable to be fully 
resolved at the baseline; however, the respective enantiomers could still be readily 
identified.  The peaks were divided for quantitation purposes by a direct dropdown at the 
point of intersection.  R-methamphetamine and S-methamphetamine were also unable to 
be resolved at the baseline, so those peaks are likewise divided by a dropdown at the point 
of intersection.  This impacts the quantitation of these analytes; in reality, there is some 
overlap between the peaks and the division at the point of intersection does not take that 
into consideration.  The calibration curves are consistent, as there is an equal concentration 
of these enantiomers to produce peaks of equivalent size, but in case studies when there is 
more of one enantiomer than the other, where those peaks are divided will vary depending 
on the most abundant enantiomer.  
 The R-enantiomer elutes prior to the S-enantiomer for amphetamine and 
methamphetamine.  Ephedrine has two chiral centers; the “2” carbon occurs at the same 
location as the chiral center in other amphetamines.  1S,2R-ephedrine has the same R-
configuration at the same carbon as R-methamphetamine and R-amphetamine and, like 
them, elutes prior to its enantiomer.  Presumably, MDA and MDMA also elute with the R-
enantiomer first. However, due to only racemic MDA and MDMA certified reference 
standards available, it cannot be definitively demonstrated.  
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4.2 Validation 
A linear and quadratic fit were assessed and, though the R2 values were comparable, 
a linear fit was ultimately the chosen form of regression.  When a quadratic curve was 
attempted, there were quantitation issues at the lower end of the curve, causing the QC low 
concentration used for the precision and bias studies to calculate below the limit of 
quantitation.  No weighting was used.  
 MDA and MDMA were purchased as racemic standards and analysis via the chiral 
column caused the racemic mixtures to split into two peaks.  Though peak ratios suggest 
that the standards were approximately a 50:50 mixture, quantitation relied on the addition 
of the peak areas to produce a separate calibration curve for both enantiomers. Thus, 
quantitation is not divided between the S- and R- enantiomers.  This in turn, affected the 
LOD and LLOQ, and although they were determined to be 10 µg/L for MDA and MDMA, 
these numbers are not precisely accurate.  Calibrators were prepared from 10-1000 µg/L 
of total MDA and MDMA. However, as the peaks were split into the enantiomers, the 
relative concentrations are also expected to be divided.  Assuming a 50:50 mixture, the 
linear range for MDA and MDMA would then range from 5-500 µg/L and subsequently 
the estimated LOD and LLOQ for these compounds would then be 5 µg/L. 
In the 24-hour processed sample stability study, most compounds remained within 
±20% of the original peak area at T0 and the exceptions were consistent over the QC low 
and QC high concentrations.  1S,2R-ephedrine and 1R,2S-ephedrine were out of the 
expected range for both the low and high concentrations, with the low reaching 124% and 
123%, respectively, and the high reaching 134% and 135%, respectively.  The QC high 
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had an additional compound out of range; R-amphetamine reached 131% at the 24-hour 
mark.  The QC low for R-amphetamine remained in range, with 109% at the 24-hour mark.  
As the largest gaps occurred for the QC high concentrations, it appears that the higher 
concentration, the more likely a compound is to fall out of range.  It may be inferred that 
any sample that contains ephedrine and is re-analyzed a day later, may be quantitated with 
an elevated concentration.  If the concentration is sufficiently high, this may be observed 
for R-amphetamine as well. However, it must be considered that the addition of internal 
standard will rectify some of these fluctuations in stability. 
 The compounds appear not at risk of dropping below 80% of the concentration over 
24 hours.  The closest a compound came to that level was MDA-1, both for the QC low 
and QC high, where it dropped to 83% and 85%, respectively.  For the QC low, the 
concentration cycled up and down, reaching 84% after 5 hours of sitting on the autosampler 
carousel, increasing to 102% at 16 hours, and finally dropping again to 83% at 24 hours.  
The concentration also cycled for the QC high, with 85% occurring after 5 hours of sitting 
on the autosampler carousel, followed by a steady increase to 111% at 16 hours, and then 
a decrease to 92% at 24 hours.  
 Matrix effects above 100% are indicative of ion enhancement; matrix effects below 
100% are indicative of ion suppression.  There was ion enhancement for all compounds, as 
the minimum average matrix effects amongst all compounds for the QC low was 267% 
and the maximum was 306%.  Likewise, for the QC high, the minimum average matrix 
effects amongst all compounds was 140% and the maximum was 200%.  The ranges are 
smaller and lower for the QC high as opposed to the QC low, which indicates that more 
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matrix effects occur with a smaller concentration than a larger concentration.  The precision 
percentage is smaller for the QC high concentrations compared to the QC low 
concentrations, indicating that the QC high values are more similar to each other than the 
QC low values, though the precision was within 15% for all analytes at both concentrations. 
 The extraction efficiency is above 50% for all analytes, indicating acceptable 
extraction.  However, the extraction efficiency for all compounds in the QC low 
concentration, with the exception of both ephedrine enantiomers, is above 100%. This 
could be an artifact of the matrix effects as they were also particularly pronounced at QC 
low concentrations. The increased variability of the matrix effects at low concentrations 
may exacerbate extraction efficiency results. In contrast, the QC high concentration has 
only one analyte with an extraction efficiency above 100%, which is R-methamphetamine 
with 108%. 
 The process efficiency results are also above 100% for all analytes, both for QC 
low and QC high concentrations.  The average process efficiency range for all analytes 
over the QC low concentration was 189%-359%.  In contrast, the average process 
efficiency range for all analytes over the QC high concentration was 105%-174%.  The 
range is both higher and broader for the QC low concentration, similar to what was seen 
with the extraction efficiency results.  The process efficiency is also over 100% for all 
analytes, which suggests that there is some outside interference causing ion enhancement.   
 All analytes except 1S,2R-ephedrine, MDA-1, and MDA-2 had at least one bias 
result fall outside ±20% range over the three concentrations tested.  MDMA-2 had the most 
dramatic bias results, with all three QC concentrations falling out of range.  The spread of 
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the bias results is relatively even across the concentrations: four QC low concentrations, 
six QC medium concentrations, and four QC high concentrations fell outside the ±20%.  
As the bias results are above the suggested SWGTOX limits, further method development 
may render this method more suitable for strict quantitation of specific amphetamine 
enantiomers.  
 Between-run precision is acceptable if the low-range results are within 20% and the 
medium and high range results are within 15%.  All results for all analytes at all three 
concentrations were within 15%, so the precision was acceptable for all analytes.  The 
highest precision value was 13.0%, which was produced by the QC high value for MDMA-
2, the analyte that had all three bias results out of range.  
 The QC low concentrations throughout the validation process had the widest range 
of values and the largest deviations, shown through the stability studies, matrix effects, 
extraction efficiencies, and process efficiencies.  Perhaps if the linear range began at a 
higher concentration, such as 50 µg/L, and extended to or above 1000 µg/L, the results for 
the matrix effects and bias would be more acceptable.  
 
4.2 Applicability to Authentic Casework 
 During the validation process, a linear calibration model was chosen and validated 
over a quadratic model.  This ended up creating a problem during the case analysis, as the 
calibrators that were run with the cases did not respond to a linear equation for most 
analytes.  Instead, the calibration fit more closely with a quadratic model and as such, the 
case studies were not able to be quantitated.  MDA and MDMA were the exceptions to 
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this, as they were the only two analytes that produced a linear curve of sufficient quality.  
The calibrator peaks for MDA-1 and MDA-2 were added together to produce a single curve 
for total MDA and the calibrator peaks for MDMA-1 and MDMA-2 were added together 
to produce a single curve for total MDMA.  Each curve had an R2 value over 0.99.  In order 
to quantify MDA and MDMA in the case studies, the separated MDA and MDMA peaks 
seen in the cases were added together to quantitate the total amount of each compound 
according to those curves.  
MDMA was found in all five cases where it had previously been seen.  In all five 
cases, both enantiomers of MDMA were seen, which was to be expected, as MDMA is 
synthesized as a racemic mixture.  Three of these cases were quantitated with an increased 
concentration over the non-chiral results and two were quantitated with a decreased 
concentration.  No long-term stability studies were performed, so it’s possible that the 
concentration could have shifted during storage.  However, much more likely, the 
quantitative results for MDMA are inaccurate based on the bias study, and so caution 
should be performed when interpreting such results.  
MDA had previously been detected in three cases and was detected in all three cases 
using this method.  However, Case 7 and Case 23, in which 30 µg/L and 12 µg/L had been 
previously found respectively, the MDA was found to be below the limit of quantitation.  
12 µg/L is close to the method’s LOQ of 10 µg/L; it’s possible that the time spent in storage 
had decreased the concentration just enough that it fell below the limit of quantitation.  30 
µg/L is more of a decrease, but these cases had been sitting in refrigerated storage for 
almost two years.  MDA has been shown to be stable in whole blood for a period of up to 
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21 weeks, but, to the author’s best knowledge, no longer-term studies have been conducted 
in blood [33].  Case 14, the other case in which MDA had been detected, was previously 
detected at a concentration of 93 µg/L and was here detected at a concentration of 108 
µg/L, within 20% of the original concentration.  
MDA was also detected in three cases where it had previously not been determined 
(Cases 3, 25, and 28).  In Cases 3 and 25, the MDA detected was below the LLOQ.  Case 
28, however, was quantified to have 43 µg/L of MDA where previously none had been 
detected.  This case was subjected to a dilution of 4; the actual detected amount was 10.7 
µg/L, which was then multiplied by the dilution factor to result in 43 µg/L.  The 10.7 µg/L 
is just above the LLOQ; in prior analysis, MDA may have been present just below that 
method’s LLOQ.  MDA is a metabolite of MDMA, and MDMA had been detected in all 
of these cases.  In all cases, both enantiomers of MDA were seen, with the exception of 
Case 25; only MDA-2 was found in this case, below the LLOQ.  
Amphetamine was identified in four cases where previously only 
methamphetamine had been detected (Cases 10, 14, 26, and 28).  Similar to MDA and 
MDMA, amphetamine is a metabolite of methamphetamine.  The amphetamine and MDA 
were likely in the samples originally as a result of metabolism, but the prior method was 
not sensitive enough to detect them.  The GC-MS amphetamine method utilized by the San 
Francisco Office of the Chief Medical Examiner has a LLOQ of 20 µg/L. The MDA and 
amphetamine detected in this method would not have been detected in prior analysis, 
demonstrating an increased sensitivity in this method compared to the prior method used. 
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Methamphetamine was detected in 18 of the 28 cases that were analyzed; all the 
methamphetamine in these 18 cases was the S-enantiomer, suggesting illicit use.  
Amphetamine was detected in 19 of the 28 cases analyzed; it too, consisted entirely of the 
S-enantiomer, with the exception of Case 8, which contained both R-amphetamine and S-
amphetamine.  As the calibration curves were not linear for these analytes, they were 
unable to be compared quantitatively.  
Two of the cases that were analyzed were reported to contain pseudoephedrine, a 
compound that was not a target analyte of this method and not investigated during the 
interference study.  Pseudoephedrine and ephedrine are diastereomers, which means they 
have the same molecular weight and very similar structures.  As seen in Cases 15 and 21, 
a peak was present that eluted slightly later than the retention time for 1R,2S-ephedrine, 
with the same ions, but in different ratios (Figure 6).  The ion ratios seen in those peaks 
were much higher than that of the ephedrine, ranging from 188.2% to 413.1% of the ion 
ratios of the positive control.  These ion ratios and the difference in retention time were 
sufficient to identify the peak seen as “non-ephedrine”.  As the non-chiral method 
identified the presence of pseudoephedrine in these cases, that peak is assumed to be 
pseudoephedrine. 
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Figure 6. Comparison of the non-ephedrine peaks to 1R,2S-ephedrine peak. The left 
shows the peak and ion ratios from the non-ephedrine peak in Case 15. The center shows 
the peak and ion ratios from the non-ephedrine peak in Case 21. The right shows the peak 
and ion ratios from the 1S,2R-ephedrine peak identified in Case 19.  
 
In seven cases, 1R,2S-ephedrine was seen where it had not been identified prior 
(Cases 9, 12, 17, 18, 19, 24, and 28).  The configuration at the second carbon in ephedrine 
is the S-enantiomer, meaning that it could be a precursor to S-methamphetamine, the 
enantiomer that was seen in all seven of these cases; its presence would be an impurity 
from the manufacture of the methamphetamine [34].  An additional possibility is that what 
was identified as 1R,2S-ephedrine is actually 1S,2S-pseudoephedrine.  The structural 
similarities between pseudoephedrine and ephedrine have made it difficult to accomplish 
chiral separation of all four of these compounds (1S,2S; 1S,2R; 1R,2R; 1R,2S) [35-37].  At 
best, three peaks have been seen for these four compounds, due to overlap between the 
enantiomers.  The qualitative (second and third transition) ion ratios that were seen in the 
“non-ephedrine” peaks in Cases 15 and 21 were extremely high. Comparably, the ion ratios 
in the peaks in these seven cases were within ±20% of the ion ratios seen in the controls.  
It seems unlikely that one pseudoephedrine enantiomer would have such a high ion ratio 
compared to the other pseudoephedrine enantiomer; the enantiomers of amphetamine, 
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ephedrine, methamphetamine, MDA, and MDMA all had similar ion ratios in this method, 
making chromatography the only way to identify them.  Therefore, it is most likely that the 
peaks identified as 1R,2S-ephedrine are actually 1R,2S-ephedrine and not an interference 
from pseudoephedrine. 
Case 13 is an interesting case; it is the only case in which the chiral method and the 
non-chiral method did not identify the same analytes.  The non-chiral method identified 
the presence of phentermine and the chiral method identified the presence of S-
amphetamine and S-methamphetamine.  No phentermine was found using the chiral 
method.  It is unknown why this happened.  Ideally, this case would be re-extracted and re-
analyzed to confirm the result, but due to time constraints, it was unable to be repeated.  
Other than Case 13, the results of this method are in agreement with what was 
previously found in the non-chiral method.  
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5. CONCLUSIONS 
An analytical method was developed that chirally separated 1S,2R-ephedrine, 
1R,2S-ephedrine, R-amphetamine, S-amphetamine, R-methamphetamine, S-
methamphetamine, ±MDMA, ±MDA, and phentermine in blood using the Phenomenex 
Lux AMP® chiral column and a typical liquid chromatography-tandem mass spectrometry 
system.  The total run time was 17.10 minutes and the validation plan was carried out 
according to SWGTOX standards. 
The linear dynamic range was 10-1000 µg/L for all analytes and the limit of 
detection was 2 µg/L for 1S,2R-ephedrine, 1R,2S-ephedrine, R-amphetamine, S-
amphetamine, R-methamphetamine, S-methamphetamine, and phentermine, and 10 µg/L 
for MDMA and MDA.  The lower limit of quantitation was 10 µg/L for all compounds. 
No interferences were found from isotope internal standards, postmortem blood, 
antemortem blood, or 85 drugs that are commonly seen in forensics cases.  No carryover 
was seen in blanks following samples containing 1000 µg/L of all analytes.   
The average matrix effects ranged from 140%-361% across all analytes.  The 
average extraction efficiency ranged from 60%-123% across all analytes.  The average 
process efficiency ranged from 105%-432% across all analytes.  
This method did not achieve baseline separation between the ephedrine and 
methamphetamine enantiomers and, though the precision results for all analytes are 
acceptable, the bias results fall outside the targeted ranges. This method can qualitatively 
separate the enantiomers; however, in order for quantitative analysis, further validations 
should be performed.  This method could be used in combination with a non-chiral method, 
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using either gas or liquid chromatography-mass spectrometry, to quantify the racemic 
result, and identify the enantiomers present using the presented method.  
The applicability of this method is dependent on the needs of the individual 
forensics laboratory.  Chiral columns are more expensive than typical reverse phased liquid 
chromatography columns; however, the savings in sample preparation time if a lab required 
high-throughput analysis could make a chiral column more efficient than derivatization.  
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6. Future Directions 
First, the bias study should be repeated in order to fully validate this method for 
quantitation purposes.  If the lower end of the calibration curve still has quantitation issues, 
then increasing the lower limit of quantitation should be considered.  
Second, pseudoephedrine was not an analyte of interest in this method, nor was it 
included in the interference study, though it is a diastereomer of ephedrine.  Further work 
could be done by either validating the method to determine that neither enantiomer of 
pseudoephedrine will cause interference in the method or adding both pseudoephedrine 
enantiomers to the method.  Following the case results, it seems that ephedrine and 
pseudoephedrine may have overlapping peaks and the effects that pseudoephedrine has on 
the method should be evaluated at minimum.  
Finally, if individual enantiomer standards become available for MDA and 
MDMA, they should be used to validate the calibration curve for the true analytical range 
for each enantiomer. This would allow each enantiomer to be quantified, and to confirm 
which enantiomer elutes first.  
57 
APPENDIX A:  
Table A: Attempted LC methods. A list of the liquid chromatography methods that 
were attempted and discarded 
 
Method Eluent A Eluent B Time 
(min) 
Gradient 
(%B) 
Flow rate 
(mL/min) 
1 5mM ammonium 
formate (pH 11) 
Methanol 0 
10 
11 
16 
16.1 
60 
60 
95 
95 
60 
0.42 
2 5mM ammonium 
formate (pH 11) 
Methanol 0 
5 
20 
20.3 
21 
10 
10 
95 
95 
10 
0.8 
3 5mM ammonium 
formate (pH 11) 
Methanol 0 
5 
20 
20.3 
21 
10 
10 
95 
95 
10 
0.42 
4 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
3 
3.1 
6 
6.1 
9 
9.1 
12 
12.1 
12.5 
50 
50 
60 
60 
70 
70 
80 
80 
95 
95 
50 
50 
0.8 
5 5mM ammonium 
formate (pH 11) 
Methanol 0 
.5 
12 
12.5 
13 
10 
10 
95 
95 
10 
0.8 
6 5mM ammonium 
formate (pH 11) 
Methanol 0 
5 
20 
20.3 
21 
10 
10 
95 
95 
10 
0.8 
7 5mM ammonium 
formate (pH 11) 
Methanol 0 
.5 
5 
11.5 
12 
13 
10 
10 
50 
95 
95 
10 
0.8 
58 
Method Eluent A Eluent B Time 
(min) 
Gradient 
(%B) 
Flow rate 
(mL/min) 
8 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
3 
3.1 
6 
6.1 
9 
9.1 
10 
50 
50 
60 
60 
65 
65 
80 
80 
50 
50 
0.8 
9 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
3 
3.1 
6 
6.1 
11 
11.1 
12 
50 
50 
60 
60 
65 
65 
80 
80 
50 
50 
0.8 
10 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
3 
3.1 
6 
6.1 
9 
9.1 
10 
50 
50 
55 
55 
60 
65 
70 
80 
50 
50 
0.8 
11 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
3 
3.1 
5 
6.1 
9 
9.1 
10 
50 
50 
55 
55 
60 
65 
70 
80 
50 
45 
0.8 
12 5mM ammonium 
formate (pH 11) 
Methanol 0 
.9 
1 
3 
4 
6 
6.1 
7 
9 
40 
40 
50 
55 
55 
65 
70 
70 
80 
0.8 
59 
Method Eluent A Eluent B Time 
(min) 
Gradient 
(%B) 
Flow rate 
(mL/min) 
13 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
3 
3.1 
6 
6.1 
9 
9.1 
15 
50 
50 
60 
60 
65 
65 
80 
80 
50 
50 
0.6 
14 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
3 
3.1 
6 
6.1 
9 
9.1 
15 
50 
50 
60 
60 
65 
65 
80 
80 
50 
50 
0.7 
15 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
3 
6 
6.1 
9 
9.1 
10 
50 
50 
60 
60 
65 
70 
80 
50 
50 
0.8 
16 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
5 
6 
6.1 
9 
9.1 
10 
50 
50 
60 
60 
65 
70 
80 
50 
50 
0.8 
17 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
6 
6.1 
9.4 
9.5 
10.5 
50 
50 
60 
60 
65 
80 
50 
50 
0.8 
60 
Method Eluent A Eluent B Time 
(min) 
Gradient 
(%B) 
Flow rate 
(mL/min) 
18 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
6 
6.1 
9.4 
9.5 
10.5 
45 
45 
50 
60 
65 
80 
45 
45 
0.8 
19 5mM ammonium 
formate (pH 11) 
Methanol 0 
7 
9.5 
10.5 
60 
60 
40 
45 
0.8 
20 5mM ammonium 
formate (pH 11) 
Methanol 0 
7 
9.5 
10.5 
11 
60 
60 
80 
80 
60 
0.8 
21 5mM ammonium 
formate (pH 11) 
Methanol 0 
7 
9.5 
10.5 
11 
60 
60 
80 
80 
60 
0.6 
22 5mM ammonium 
formate (pH 11) 
Methanol 0 
13 
60 
60 
0.6 
23 5mM ammonium 
formate (pH 11) 
Methanol 0 
3 
3.1 
7 
10.5 
11 
50 
50 
60 
60 
80 
60 
0.6 
24 5mM ammonium 
formate (pH 11) 
Methanol 0 
11 
50 
50 
0.6 
25 5mM ammonium 
formate (pH 11) 
Methanol 0 
11 
55 
55 
0.8 
26 5mM ammonium 
formate (pH 11) 
Methanol 0 
7 
9.5 
10 
55 
55 
60 
55 
0.8 
27 5mM ammonium 
formate (pH 11) 
Methanol 0 
7 
12.5 
13 
55 
55 
60 
55 
0.8 
28 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.05% 
formic acid 
0 
7 
12.5 
13 
55 
55 
60 
55 
0.8 
29 5mM ammonium 
formate (pH 11) 
Acetonitrile 0 
7 
12.5 
13 
55 
55 
60 
55 
0.8 
61 
Method Eluent A Eluent B Time 
(min) 
Gradient 
(%B) 
Flow rate 
(mL/min) 
30 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.05% 
formic acid 
0 
1 
1.1 
3 
3.1 
6 
6.1 
9 
9.1 
10 
40 
40 
45 
45 
50 
50 
55 
55 
40 
40 
0.8 
31 5mM ammonium 
formate (pH 11) 
Acetonitrile 0 
1 
1.1 
3 
3.1 
6 
6.1 
9 
9.1 
10 
40 
40 
45 
45 
50 
50 
55 
55 
40 
40 
0.8 
32 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.05% 
formic acid 
0 
7 
11 
12 
45 
45 
55 
45 
0.8 
33 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.05% 
formic acid 
0 
1 
10 
10.5 
40 
40 
55 
40 
0.8 
34 5mM ammonium 
formate (pH 11) 
Methanol  0 
1 
13 
13.5 
50 
50 
65 
50 
0.8 
35 5mM ammonium 
formate (pH 11) 
Methanol  0 
10 
50 
50 
1.2 
36 5mM ammonium 
formate (pH 11) 
Methanol  0 
10 
60 
60 
1.2 
37 5mM ammonium 
formate (pH 11) 
Acetonitrile 0 
12 
35 
35 
0.8 
38 5mM ammonium 
formate (pH 11) 
Acetonitrile 0 
12 
10 
10 
0.8 
39 5mM ammonium 
formate (pH 11) 
Acetonitrile 0 
1 
1.1 
10 
10.1 
11.5 
12 
20 
20 
25 
25 
35 
35 
20 
1.0 
40 5mM ammonium 
formate (pH 11) 
Acetonitrile 0 
12 
25 
25 
1.0 
62 
Method Eluent A Eluent B Time 
(min) 
Gradient 
(%B) 
Flow rate 
(mL/min) 
41 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.05% 
formic acid 
0 
3 
3.1 
5 
5.1 
8 
8.1 
12 
12.1 
13 
40 
40 
45 
45 
50 
50 
55 
55 
40 
40 
0.8 
42 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.05% 
formic acid 
0 
3 
3.1 
7 
7.1 
12 
12.1 
16 
16.1 
20 
40 
40 
45 
45 
50 
50 
55 
55 
40 
40 
0.42 
43 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.05% 
formic acid 
0 
2 
2.1 
5 
5.1 
8.5 
8.6 
12 
12.1 
15 
15.5 
40 
40 
45 
45 
50 
50 
55 
55 
60 
60 
40 
0.6 
44 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.05% 
formic acid 
0 
1 
1.1 
5 
5.1 
10 
10.1 
15 
15.1 
16 
40 
40 
45 
45 
50 
50 
55 
55 
40 
40 
0.42 
45 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
1.1 
4 
4.1 
8 
8.1 
12 
12.1 
13 
50 
50 
60 
60 
65 
65 
80 
80 
50 
50 
0.5 
63 
Method Eluent A Eluent B Time 
(min) 
Gradient 
(%B) 
Flow rate 
(mL/min) 
46 5mM ammonium 
formate (pH 11) 
Methanol 0 
12 
55 
75 
0.5 
47 5mM ammonium 
formate (pH 11) 
Methanol 0 
15 
55 
55 
0.8 
48 5mM ammonium 
formate (pH 11) 
Methanol 0 
15 
51 
55 
0.8 
49 5mM ammonium 
formate (pH 11) 
Methanol 0 
30 
45 
55 
0.8 
50 5mM ammonium 
formate (pH 11) 
Methanol 0 
3 
15 
20 
21 
40 
40 
45 
47 
40 
0.8 
51 5mM ammonium 
formate (pH 11) 
Methanol 0 
30 
31 
40 
55 
40 
0.8 
52 5mM ammonium 
formate (pH 11) 
Methanol 0 
.5 
12 
12.1 
20 
20.5 
38 
38 
43 
43 
45 
38 
0.8 
53 5mM ammonium 
formate (pH 11) 
Methanol 0 
1.5 
9.5 
9.6 
18 
18.5 
39 
39 
44 
46 
50 
38 
0.8 
54 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
13 
13.1 
23 
23.5 
40 
40 
46 
52 
55 
40 
0.8 
55 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
8 
12 
12.1 
24.5 
25 
40 
40 
43 
43 
46 
52 
40 
0.8 
56 5mM ammonium 
formate (pH 11) 
Methanol 0 
1 
6 
6.1 
12 
12.1 
22 
22.5 
40 
40 
42 
44 
46 
49 
53 
40 
0.8 
64 
Method Eluent A Eluent B Time 
(min) 
Gradient 
(%B) 
Flow rate 
(mL/min) 
57 5mM ammonium 
formate (pH 11) 
Methanol 0 
25 
25.5 
45 
55 
45 
0.8 
58 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.05% 
formic acid 
0 
35 
35.5 
35 
45 
35 
0.8 
59 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.025% 
formic acid 
0 
60 
60.5 
35 
55 
35 
0.8 
60 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.025% 
formic acid 
0 
10 
10.1 
25.5 
26 
35 
37 
40 
45 
35 
0.8 
61 5mM ammonium 
formate (pH 11) 
Methanol 
with 0.05% 
formic acid 
0 
10 
10.1 
25.5 
26 
35 
37 
40 
45 
35 
1.0 
62 5mM ammonium 
formate (pH 9) 
Methanol 0 
20 
40 
40 
0.8 
63 5mM ammonium 
formate (pH 9) 
Methanol 0 
20 
35 
35 
0.8 
64 5mM ammonium 
formate (pH 7.4) 
Methanol 0 
20 
35 
35 
0.8 
65 5mM ammonium 
formate (pH 11) 
Methanol 0 
7 
15 
15.5 
55 
55 
60 
55 
0.8 
66 5mM ammonium 
formate (pH 11) 
Methanol 0 
7 
7.1 
14 
14.5 
45 
50 
55 
60 
45 
0.8 
67 5mM ammonium 
formate (pH 11) 
Methanol 0 
5 
5.1 
12 
17 
17.5 
42 
45 
50 
55 
60 
40 
0.8 
68 5mM ammonium 
formate (pH 11) 
Methanol 0 
4 
4.1 
10 
10.1 
18 
18.1 
41 
41 
54 
54 
55 
60 
41 
0.8 
65 
Method Eluent A Eluent B Time 
(min) 
Gradient 
(%B) 
Flow rate 
(mL/min) 
69 5mM ammonium 
formate (pH 11) 
Methanol 0 
3 
3.1 
8 
8.1 
17 
17.1 
41 
41 
52 
54 
56 
60 
41 
0.8 
70 5mM ammonium 
formate (pH 11) 
Methanol 0 
3 
3.1 
8 
8.1 
20 
20.1 
40 
41 
55 
57 
57 
60 
40 
0.5 
71 65:20:10:5 mixture of 
5mM ammonium 
formate (pH 11): 
methanol:acetonitrile: 
Isopropanol 
 0 
20 
0 
0 
0.8 
72 5mM ammonium 
formate (pH 11) 
Methanol 0 
3 
3.1 
8 
8.1 
16 
16.1 
40 
41 
55 
57 
57 
60 
39 
0.8 
73 5mM ammonium 
formate (pH 11) 
Methanol 0 
3 
3.1 
8 
8.1 
16 
16.1 
39 
30 
56 
56 
57 
60 
42 
0.8 
74 5mM ammonium 
formate (pH 11) 
Methanol 0 
3 
3.1 
9 
9.1 
18 
18.1 
42 
43 
50 
52 
57 
60 
50 
0.8 
75 5mM ammonium 
formate (pH 11) 
Methanol 0 
10 
10.1 
20 
20.1 
50 
50 
55 
60 
50 
0.8 
76 70:30 ammonium 
carbonate:methanol 
Methanol 
with 0.025% 
formic acid 
0 
20 
0 
10 
0.8 
77 70:30 ammonium 
carbonate:methanol 
Methanol 
with 0.025% 
formic acid 
0 
25 
5 
15 
0.8 
66 
Method Eluent A Eluent B Time 
(min) 
Gradient 
(%B) 
Flow rate 
(mL/min) 
78 70:30 ammonium 
carbonate:methanol 
Methanol 
with 0.025% 
formic acid 
0 
25 
5 
20 
0.6 
 
79 5mM ammonium 
formate (pH 11) 
Methanol 0 
3 
3.1 
6 
6.1 
20 
20.5 
42 
43 
46 
47 
50 
60 
42 
0.8 
80 5mM ammonium 
formate (pH 11) 
Methanol 0 
3 
3.1 
18 
18.5 
45 
45 
55 
60 
45 
0.8 
81 5mM ammonium 
formate (pH 11) 
Methanol 0 
2 
2.1 
4 
4.1 
6 
6.1 
8 
8.1 
18 
40 
41 
43 
44 
45 
46 
47 
49 
50 
60 
0.8 
82 5mM ammonium 
formate (pH 11) 
Methanol 0 
5 
5.1 
10 
10.1 
20 
40 
40 
46 
46 
55 
60 
0.8 
83 5mM ammonium 
formate (pH 11) 
Methanol 0 
20 
40 
60 
0.8 
84 5mM ammonium 
formate (pH 11) 
Methanol 0 
10 
39 
43 
0.8 
85 5mM ammonium 
formate (pH 11) 
Methanol 0 
10 
40 
42 
0.8 
86 5mM ammonium 
formate (pH 11) 
Methanol 0 
10 
41 
42 
0.8 
87 5mM ammonium 
formate (pH 11) 
Methanol 0 
10 
43 
45 
0.8 
88 5mM ammonium 
formate (pH 11) 
Methanol 0 
10 
50 
52 
0.8 
89 5mM ammonium 
formate (pH 11) 
Methanol 0 
15 
39 
43 
0.8 
90 5mM ammonium 
formate (pH 11) 
Methanol 0 
15 
40 
42 
0.8 
91 5mM ammonium 
formate (pH 11) 
Methanol 0 
15 
41 
42 
0.8 
92 5mM ammonium 
formate (pH 11) 
Methanol 0 
15 
46 
48 
0.8 
67 
Method Eluent A Eluent B Time 
(min) 
Gradient 
(%B) 
Flow rate 
(mL/min) 
93 5mM ammonium 
formate (pH 11) 
Methanol 0 
15 
49 
52 
0.8 
94 5mM ammonium 
formate (pH 11) 
Methanol 0 
15 
50 
52 
0.8 
95 5mM ammonium 
bicarbonate (pH 11) 
Methanol 0 
10 
11 
16 
16.3 
60 
60 
95 
95 
60 
0.42 
96 5mM ammonium 
bicarbonate (pH 11) 
Methanol 0 
10 
11 
16 
16.3 
60 
60 
95 
95 
60 
0.8 
97 5mM ammonium 
bicarbonate (pH 11) 
Methanol 0 
.5 
3 
3.1 
9 
9.1 
17 
17.1 
42 
42 
43 
50 
52 
57 
60 
42 
0.8 
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